CADRENAL THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.46 USD | -5.23% |
|
-6.22% | -37.83% |
Valuation
| Fiscal Period: December | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| Capitalization 1 | 9.636 | 7.364 | - | - |
| Enterprise Value (EV) 1 | 9.636 | 7.364 | 7.364 | 7.364 |
| P/E ratio | -1.19 x | -1.28 x | -1.35 x | -1.33 x |
| Yield | - | - | - | - |
| Capitalization / Revenue | - | - | - | - |
| EV / Revenue | - | - | - | - |
| EV / EBITDA | -1.26 x | -0.73 x | -0.61 x | -0.5 x |
| EV / FCF | - | - | - | - |
| FCF Yield | - | - | - | - |
| Price to Book | - | - | - | - |
| Nbr of stocks (in thousands) | 13,023 | 16,008 | - | - |
| Reference price 2 | 0.7399 | 0.4600 | 0.4600 | 0.4600 |
| Announcement Date | 3/11/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - |
| EBITDA 1 | - | -7.631 | -10.1 | -12 | -14.7 |
| EBIT 1 | - | -7.633 | -8.215 | -10.24 | -12.7 |
| Operating Margin | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | - | -8.357 | -7.968 | -10.06 | -12.43 |
| Net income 1 | -6.714 | -8.357 | -7.968 | -10.06 | -12.43 |
| Net margin | - | - | - | - | - |
| EPS 2 | -0.8500 | -0.6200 | -0.3600 | -0.3400 | -0.3450 |
| Free Cash Flow | - | - | - | - | - |
| FCF margin | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - |
| Announcement Date | 3/30/23 | 3/11/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - |
| EBITDA 1 | - | -1.263 | -1.756 | -2.1 | -2.9 | -3.4 |
| EBIT 1 | - | -1.264 | -1.756 | -1.78 | -2.302 | -2.602 |
| Operating Margin | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | - | -1.144 | -1.663 | -1.698 | -2.215 | -2.598 |
| Net income 1 | -1.036 | -1.144 | -1.663 | -1.698 | -2.215 | -2.598 |
| Net margin | - | - | - | - | - | - |
| EPS 2 | -0.0700 | -0.0500 | -0.1000 | -0.0850 | -0.0900 | -0.1050 |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 11/9/23 | 3/11/24 | 5/9/24 | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - |
| Net Cash position | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - |
| ROE (net income / shareholders' equity) | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - |
| Assets 1 | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - |
| Capex | - | - | - | - | - |
| Capex / Sales | - | - | - | - | - |
| Announcement Date | 3/30/23 | 3/11/24 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
0.46
USD
Average target price
3.5
USD
Spread / Average Target
+660.87%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -37.83% | 7.36M | |
| +30.38% | 684B | |
| +29.58% | 568B | |
| -4.36% | 361B | |
| +19.30% | 329B | |
| +3.73% | 284B | |
| +16.04% | 240B | |
| +9.28% | 208B | |
| -7.24% | 200B | |
| +7.68% | 166B |
- Stock Market
- Equities
- CVKD Stock
- Financials Cadrenal Therapeutics, Inc.